Although KAMELEON was terminated prematurely due to recruitment difficulty, the study demonstrated that patients with HER2‐positive urothelial bladder cancer or pancreatic cancer can respond to T‐DM1. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.